ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Esmolol Hydrochloride In Plastic Container, and when can generic versions of Esmolol Hydrochloride In Plastic Container launch?
Esmolol Hydrochloride In Plastic Container is a drug marketed by Hq Spclt Pharma and is included in one NDA. There are two patents protecting this drug.
The generic ingredient in ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER is esmolol hydrochloride. There is one drug master file entry for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the esmolol hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Esmolol Hydrochloride In Plastic Container
A generic version of ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER was approved as esmolol hydrochloride by HIKMA on August 10th, 2004.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER?
- What are the global sales for ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER?
- What is Average Wholesale Price for ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER?
Summary for ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 87 |
| Clinical Trials: | 130 |
| Patent Applications: | 811 |
| DailyMed Link: | ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER at DailyMed |
Recent Clinical Trials for ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| John Basmaji | PHASE1 |
| Western University, Canada | PHASE1 |
| London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | PHASE1 |
See all ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER clinical trials
Pharmacology for ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER
| Drug Class | beta-Adrenergic Blocker |
| Mechanism of Action | Adrenergic beta-Antagonists |
US Patents and Regulatory Information for ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER is protected by two US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hq Spclt Pharma | ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER | esmolol hydrochloride | SOLUTION;INTRAVENOUS | 205703-001 | Apr 7, 2016 | RX | Yes | Yes | 8,829,054 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Hq Spclt Pharma | ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER | esmolol hydrochloride | SOLUTION;INTRAVENOUS | 205703-001 | Apr 7, 2016 | RX | Yes | Yes | 8,835,505 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER
See the table below for patents covering ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Argentina | 035416 | UNA COMPOSICION FARMACEUTICA ESTERIL Y EL METODO PARA PREPARARLA | ⤷ Start Trial |
| Argentina | 098013 | UNA COMPOSICIÓN FARMACÉUTICA ACUOSA ESTÉRIL, LISTA PARA SU USO, ADECUADA PARA LA ADMINISTRACIÓN PARENTERAL, MEDIANTE INFUSIÓN PARA EL TRATAMIENTO DE CONDICIONES CARDÍACAS, ENVASADA EN UN RECIPIENTE SELLADO, Y QUE POSEE UN pH ENTRE 3,5 Y 6,5, Y MÉTODO PARA SU FABRICACIÓN | ⤷ Start Trial |
| Austria | 341319 | ⤷ Start Trial | |
| Australia | 2002309475 | ⤷ Start Trial | |
| Brazil | 0203517 | ⤷ Start Trial | |
| Canada | 2410446 | FORMULATION D'ESMOLOL (ESMOLOL FORMULATION) | ⤷ Start Trial |
| China | 1298320 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch